Clinical Trial Update: Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of OMS721 in thrombotic microangiopathies has completed. Results of the trial have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Microangiopathy

Drugs mentioned

• Narsoplimab (OMS721) (narsoplimab)

Snippet

Sponsor: Omeros Corporation | Conditions: Thrombotic Microangiopathies | Phase 2 | Status: COMPLETED | Results posted: 2024-08-28